Myriad Genetics, Inc.  

(Public, NASDAQ:MYGN)   Watch this stock  
Find more results for Strategic Diagnostics Inc.�
40.08
+0.40 (1.01%)
After Hours: 40.50 +0.42 (1.05%)
Apr 24, 7:18PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 38.35 - 40.83
52 week 20.02 - 42.50
Open 39.91
Vol / Avg. 1.73M/2.04M
Mkt cap 2.92B
P/E 17.21
Div/yield     -
EPS 2.33
Shares 72.97M
Beta 0.59
Inst. own 149%
May 6, 2014
Q3 2014 Myriad Genetics Earnings Conference Call - 4:30PM EDT - Add to calendar
May 6, 2014
Q3 2014 Myriad Genetics Earnings Release - 4:00PM EDT - Add to calendar
Feb 4, 2014
Q2 2014 Myriad Genetics Earnings Conference Call - Webcast
Feb 4, 2014
Q2 2014 Myriad Genetics Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 24.68% 24.00%
Operating margin 40.67% 37.18%
EBITD margin - 38.63%
Return on average assets 26.26% 19.69%
Return on average equity 29.57% 21.57%
Employees 1,325 -
CDP Score - -

Address

320 Wakara Way
SALT LAKE CITY, UT 84108
United States - Map
+1-801-5843600 (Phone)
+1-801-5843640 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

Officers and directors

John T. Henderson M.D. Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Peter D. Meldrum President, Chief Executive Officer, Director
Age: 65
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Walter M. Gilbert Ph.D. Independent Vice Chairman of the Board
Age: 81
Bio & Compensation  - Reuters
James S. Evans Chief Financial Officer, Treasurer
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
T. Craig Benson President of Myriad RBM, Inc.
Age: 51
Bio & Compensation  - Reuters
Mark C. Capone President of Myriad Genetic Laboratories, Inc.
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard M. Marsh Esq. Executive Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Jayne B. Hart Executive Vice President - Human Resources
Age: 53
Bio & Compensation  - Reuters
Gary A. King Executive Vice President - International Operations
Age: 57
Bio & Compensation  - Reuters
Ronald S. Rogers Executive Vice President - Corporate Communications
Age: 45
Bio & Compensation  - Reuters